NewAmsterdam Pharma Company N.V.

NASDAQ•NAMS

執行長: Dr. Michael Harvey Davidson FACC, Facp., M.D.

板塊: Healthcare

行業: Biotechnology

上市日期: 2021-02-09

NewAmsterdam Pharma Company N.V., a late-stage biopharmaceutical company, develops therapies to enhance patient care in populations with metabolic disease. It is developing obicetrapib, an oral low-dose cholesteryl ester transfer protein (CETP) inhibitor, that is in various clinical trials as a monotherapy and a combination therapy with ezetimibe for lowering LDL-C for cardiovascular diseases. The company also develops Obicetrapib which is in Phase 2a clinical trial for Alzheimer's disease. NewAmsterdam Pharma Company N.V. is headquartered in Naarden, the Netherlands.

聯絡資訊

Gooimeer 2-35, Naarden, 1411 DC, Netherlands

31-35-206-2971

www.newamsterdampharma.com

市值

$3.96B

本益比 (TTM)

-19.3

19.2

股息率

52周最高

$42.00

52周最低

$15.70

52周範圍

71%

排名59Top 87.6%

2.2

F-Score

改良版 Piotroski 分析

基於 5 年期基本面

疲弱 • 2.2 / 9 分

評分區間 (0-9)

8-9: 價值優異

6-7: 基本面強勁

4-5: 整體穩健

0-3: 表現疲弱

資料區間: 2021-2025

財務儀表板

Q4 2025 數據

營業收入

$32.00K+0.00%

近4季度走勢

每股收益

-$0.65+0.00%

近4季度走勢

自由現金流

-$40.98M+0.00%

近4季度走勢

2025 Annual 財報亮點

核心亮點

Phase 3 Trials Met Endpoints Obicetrapib met primary LDL-C lowering endpoints in BROADWAY and BROOKLYN Phase 3 trials, showing strong efficacy.

Menarini Regulatory Submissions Complete MAAs submitted to EMA/UK/Switzerland for obicetrapib; decisions anticipated in second half of 2026.

Operating Loss Decreased Annual loss for the year narrowed by $37.8M to $203.8M, despite revenue falling 50.6% to $22.5M.

Cash Position Supports Operations Ending cash, equivalents, and restricted cash totaled $491.3M as of December 31, 2025, sufficient for near-term needs.

關注風險

Clinical Stage and Profitability Risk Company remains clinical-stage, incurred $203.8M loss in 2025, and anticipates continued significant losses indefinitely.

Substantial Financing Required Requires substantial additional capital to achieve goals; failure to secure funding could delay or terminate product development efforts.

Increased Cash Used Investing Cash used in investing activities rose sharply to $174.9M in 2025, contributing to a $280.4M decrease in total cash balance.

Dependence on Obicetrapib Success Future success entirely dependent on successful clinical development, regulatory approval, and commercialization of obicetrapib.

未來展望

Complete PREVAIL Cardiovascular Outcomes Continue executing PREVAIL CVOT to evaluate MACE benefit; earliest conclusion expected end of 2026 or later.

Await European Regulatory Decisions Anticipate Menarini receiving regulatory decisions on MAAs from European regulators in the second half of 2026.

Initiate Alzheimer's Disease Trial Expect to initiate a new clinical trial evaluating obicetrapib in patients with early Alzheimer’s disease during 2026.

Pursue US Commercialization Strategy Current plan focuses on pursuing development and commercialization in the United States ourselves, considering additional partners.

同行對比

營業收入 (TTM)

ARWR

$1.09B

+4081.8%

LGND

$268.09M

+60.4%

SLNO

$190.41M

+0.0%

毛利率 (最新季度)

KYMR

2763.6%

-2680.7pp

LGND

143.6%

+2.6pp

CRNX

111.8%

+0.0pp

關鍵指標

股票代碼	市值	本益比 (TTM)	股東權益報酬率 (TTM)	負債率
ARWR	$9.34B	46.2	36.1%	19.5%
KYMR	$7.34B	-24.4	-29.1%	4.7%
PRAX	$7.26B	-25.5	-58.7%	0.0%

長期趨勢

近4季度

營業收入

淨利

營運現金流

4季度營業收入複合增長率

-77.9%

增長承壓

4季度淨利複合增長率

N/M

盈利狀態轉變

現金流穩定性

現金流需要關注

深度研究

下次財報:2026年5月6日

每股收益:-

營業收入:-

財務數據

電話會議

財務報告

新聞

損益表

資產負債表

現金流量表

財務比率

變化率

損益表	過去12個月

無資料